朱朝晖，男，1969年生人。现任中国医学科学院北京协和医院医学科学研究中心常务副主任（主持工作），核医学科主任医师、党支部书记，北京协和医学院“协和学者”特聘教授，博士生导师。学术任职有中华医学会核医学分会常委/PET学组组长，中国医学装备协会核医学装备与技术专委会常委，中国医疗保健国际交流促进会神经内分泌肿瘤分会（CNETS）常委，中国生物物理学会分子影像分会委员，《协和医学》杂志副主编等。1995年毕业于中国协和医科大学医学八年制，获医学博士学位。迄今一直从事临床核医学诊疗工作。开展了10余种核医学分子影像新药物、新技术的国际首次临床转化。先后主持国家重点研发计划、国家自然科学基金等20余项课题研究。以第一和/或通讯作者发表国际高影响力期刊杂志文章60余篇，包括专业领域国际顶级刊物文章30余篇。参与20余部专业性著作编写。获省部级科技奖一等奖2项、二奖项6项等。近三年以通讯作者发表的英文论著：1.Asingle-arm,low-dose,prospectivestudyof177Lu-EB-PSMAradioligandtherapyinpatientswithmetastaticcastration-resistantprostatecancer.JNuclMed.2022Nov3:jnumed.122.264857.IF:11.0822.Safetyandefficacyofpeptidereceptorradionuclidetherapywith177Lu-DOTA-EB-TATEinpatientswithmetastaticneuroendocrinetumors.Theranostics.2022Sep6;12(15):6437-6445.IF:11.6003.Apilotstudyof68Ga-PSMA-617PET/CTimagingand177Lu-EB-PSMA-617radioligandtherapyinpatientswithadenoidcysticcarcinoma.EJNMMIRes.2022Aug19;12(1):52.IF:3.4344.Aprospectivehead-to-headcomparisonof68Ga-NOTA-3P-TATE-RGDand68Ga-DOTATATEinpatientswithgastroenteropancreaticneuroendocrinetumours.EurJNuclMedMolImaging.2022Oct;49(12):4218-4227.IF:10.0575.Head-to-headcomparisonof[68Ga]Ga-P16-093and[68Ga]Ga-PSMA-617indynamicPET/CTevaluationofthesamegroupofrecurrentprostatecancerpatients.EurJNuclMedMolImaging.2022Feb;49(3):1052-1062.IF:10.0576.PrognosticvalueofFDGPET/CTinpatientswithneuroendocrinecarcinomaoftheuterinecervix.ClinNuclMed.2021Dec1;46(12):971-976.IF:10.7827.Head-to-headcomparisonof68Ga-DOTATATEPET/CTand18F-FDGPET/CTinlocalizingtumorswithectopicadrenocorticotropichormonesecretion:aprospectivestudy.EurJNuclMedMolImaging.2021Dec;48(13):4386-4395.IF:10.0578.Ga-68EDTAaerosolsinevaluationofinhaled-particledepositionandclearanceofobstructivepulmonarydiseases:ApilotprospectivestudycomparedwithGalligas.EurJClinInvest.2021Dec;51(12):e13620.IF:5.7229.Resectionandsurvivaldatafromaclinicaltrialofglioblastomamultiforme-specificIRDye800-BBNfluorescence-guidedsurgery.BioengTranslMed.2020Aug31;6(1):e10182.IF:10.68410.Peptidereceptorradionuclidetherapyoflate-stageneuroendocrinetumorpatientswithmultiplecyclesof177Lu-DOTA-EB-TATE.JNuclMed.2021Mar;62(3):386-392.IF:11.60011.177Lu-EB-PSMAradioligandtherapywithescalatingdosesinpatientswithmetastaticCastration-resistantprostatecancer.JNuclMed.2020Dec;61(12):1772-1778.IF:11.60012.Combined68Ga-NOTA-Evansbluelymphoscintigraphyand68Ga-NOTA-RM26PET/CTevaluationofsentinellymphnodemetastasisinbreastcancerpatients.BioconjugChem.2020Feb19;31(2):396-403.IF:6.06913.DoseescalationofanEvansblue-modifiedradiolabeledsomatostatinanalog177Lu-DOTA-EB-TATEinthetreatmentofmetastaticneuroendocrinetumors.EurJNuclMedMolImaging.2020Apr;47(4):947-957.IF:10.057